Browsing Tag
Berkeley
5 posts
Why is Caribou Biosciences ending CAR-T development before a planned phase 3 trial?
Caribou Biosciences is winding down its allogeneic CAR-T programmes and sharply reducing its workforce after financing constraints overtook clinical progress, leaving $113.8 million of mid-year liquidity and its genome-editing assets at the centre of a strategic review.
Rigetti Computing (NASDAQ: RGTI) rides a $2bn quantum funding wave into late 2026
Rigetti Computing (NASDAQ: RGTI) makes US$4.4m a quarter and is worth billions. A US$2bn federal quantum push is now deciding whether the bet pays.
Agenus–Zydus $141m immuno-oncology deal sets stage for global BOT/BAL expansion and U.S. biologics manufacturing pivot
Agenus partners with Zydus in a $141M deal to expand BOT/BAL globally and transfer U.S. biologics assets—find out what it means for cancer immunotherapy.
Roche to acquire Carmot Therapeutics to expand obesity treatment portfolio
Roche announced its definitive agreement to acquire Carmot Therapeutics, Inc., based in Berkeley, California, for an upfront purchase…
Arthur J. Gallagher acquires HR service provider Koff & Associates
Arthur J. Gallagher & Co. has acquired Kaneko & Krammer Corp, dba Koff & Associates, and based in…